Suppression of c-myc has been implicated as a critical event in some glucocorticoid-evoked apoptotic systems. It is therefore of interest to understand the mechanism of glucocorticoid-regulation of the c-myc gene. In the present study, a detailed analysis of dexamethasone (Dex)-evoked regulation of the human c-myc gene in human leukemic CEM-C7 cells has been performed. Dex suppresses c-myc mRNA and immunoreactive protein expression in clone CEM-C7 and subclone CEM-C7-14 cells. Nuclear run-on assays suggested that the regulation occurred at the level of transcription initiation. The half-life of c-myc mRNA was approximately 30 min and its stability was not affected by Dex treatment. In addition, Dex suppressed luciferase gene expression driven by − 2052 to +34 bp c-myc promoter in transfected CEM-C7-14 cells. This result further supports that c-myc gene is suppressed by Dex at the transcriptional level in apoptotic human leukemic cells.
Introduction
The proto-oncogene c-myc is important for both cell proliferation and cell death [1] . Suppression of c-myc has been found to be part of various apoptotic induction pathways [2] [3] [4] [5] [6] [7] [8] . By using antisense and over-expressed c-myc, it has been demonstrated that rapid, strong suppression of c-myc is critical for glucocorticoid-induced apoptosis of sensitive clones of human leukemic lymphoblasts [2] . This occurs well before the cells start to become apoptotic. However, it is not clear how c-myc is regulated by glucocorticoids.
The product of c-myc gene is a 64 -67 kDa nuclear transcription factor c-Myc, part of a complex family of proteins important for cell growth and viability [9] . The half-life of both c-myc mRNA and c-Myc protein is very short, varying between 30 and 60 min in different systems. The regulation of the c-myc gene and its products occurs by various mechanisms, including transcriptional, post-transcriptional, translational and combinations of these [1, 10] . In vivo, the c-myc gene is transcribed from promoters P 0 , P 1 , P 2 and P 3 , but in most cells, the P 1 and P 2 promoters within the untranslated exon I are the two major promoters, with the P 2 promoter predominating [10, 11] . In addition to transcriptional initiation, the c-myc gene can be regulated by attenuation of its transcription. Sequences located at the 3% end of exon I provide a signal leading to the failure of retention of RNA polymerase, thereby controlling mRNA elongation [12, 13] . There are also known post-transcriptional mechanisms of control of c-myc mRNA, and c-Myc protein stability can be regulated independently.
Glucocorticoids exert a classic apoptotic effect on lymphoid cells, and several oncogenically transformed cell lines have been used to study it. Often glucocorticoids have been shown to suppress the expression of c-myc in such cell lines, including mouse S49 [14] and P1798 [15] , and human CEM-C7 cells [16] . When active glucocorticoid receptor (GR) is provided by transfection, the expression of c-myc is also reduced by glucocorticoids in human Jurkat cells [4] . Studies of the mechanism of glucocorticoid down-regulation of c-myc have produced contrasting results. In P1798 cells, such regulation has been shown to be primarily at a transcriptional level [11, 15] . In CEM 1.3 cells, however, Maroder et al. reported that the glucocorticoid dexamethasone (Dex) did not affect transcription, but mainly altered the stability of c-myc mRNA [17] . Because of the discrepancy in these results, we investigated further the control of c-myc by Dex, using CEM-C7 cells. In this paper it is demonstrated that in these cells c-myc gene expression is primarily regulated by Dex at the transcriptional level.
Materials and methods

Cell lines
The glucocorticoid-sensitive cell clone CEM-C7 [18] was derived from the CCRF-CEM cell line, grown from a female patient with acute lymphoblastic leukemia. CEM-C7-14 is a subclone of CEM-C7 cell clone. The subclone has the same phenotype as the original CEM-C7 cells, including diploid karyotype, growth, sensitivity to Dex, and GR content.
Protein extraction and Western blot
Cells were washed with isotonic phosphate-buffered saline (PBS) at 4°C and resuspended in lysis buffer: 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EGTA, 1% Nonidet P-40, 20 mM leupeptin, and 400 mM 4-[2-aminoethyl] benzensulfonyl fluoride. The cellular lysates were centrifuged at 30 000 rpm for 30 min, at 4°C using Beckman TL-100 ultracentrifuge (Beckman Instruments, Palo Alto, CA). The supernatants were removed to fresh tubes. Protein concentration of the extract was then estimated using a protein assay kit (Bio-Rad Laboratories, Hercules, CA). In all samples, 2-mercaptoethanol was added to a final concentration of 5%. Whole cell extracts containing equal amounts (50 mg) of protein were electrophoresed in 10% polyacrylamide minigels (Bio-Rad) containing SDS and transferred to nylon membranes (Bio-Rad) using a semidry electroblotter (Integrated Separation Systems, Hyde Park, MA). After incubation in 10% dry milk powder in PBS, the membranes were incubated sequentially in PBS containing a solution of 5% powdered milk and the c-Myc monoclonal antibody and HRP conjugated secondary antibody. The monoclonal c-Myc antibody Myc1-9E-10.2, raised against a synthetic peptide in the COOH-terminal region of c-Myc, was generated as a culture supernatant of the hybridoma cell line CRL1729, purchased from American Type Culture Collection (Rockville, MD). After washing with PBS, the membranes were incubated for 5 min in the horseradish peroxide substrate (Pierce Chemical Company, Rockford, IL), and exposed to photographic film (Eastman Kodak Company, Rochester, NY) using various times of exposure to assure that evaluations for quantification of the signals were within the linear response range. The densitometric analysis of c-Myc protein was performed using an Image Analyser (Applied Imaging Corporation, Santa Clara, CA).
Nuclei isolation and nuclear run-on assay
Nuclei from CEM-C7 cells were isolated according to published methods (Current Protocols in Molecular Biology, Supplement 26, 1994). Briefly, cells were cultured as described above, and resuspended in an iso-osmotic buffer (0.32 M sucrose, 3 mM CaCl 2 , 2 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCl, pH 8.0, 1 mM DTT, 0.5% [v/v] Nonidet P-40). The nuclei were obtained by layering the lysed cell suspension on a sucrose cushion (2 M sucrose, 5 mM magnesium acetate, 0.1 mM EDTA, 10 mM Tris-HCI, pH 8.0, 1 mM DTT) and subjecting the samples to ultracentrifugation at 19 000 rpm at 4°C in a SW 50.1 rotor, for 47 min with slow acceleration and deceleration. Nuclei were immediately frozen and stored at − 70°C until used in the assays. Nuclear run-on transcription assay was carried out according to Mahajan [19] with minor revisions. In a final volume of 400 ml, 200 ml of the nuclear suspension was mixed with the nuclear run-on transcription mixture (0.5 M Tris-HCl, pH 7.8, 0.25 M NaCl, 1.75 M ammonium sulfate, 10 mM EDTA), 0.2 M MnCl 2 , 20 mg/ml heparin, a mixture of ATP, GTP, and CTP (20 mM stock), and labeled UTP (600 Ci/mmol, ICN Pharmaceuticals, Costa Mesa, CA). The reaction mixture was incubated at 30°C for 45 min followed by the addition of yeast tRNA (1 mg/ml), 20 mM Tris-HCl, pH 7.5, 10 mM CaCl 2 , and a solution of DNase I with proteinase K (v/v, 1:1). The samples were incubated for 30 min at 37°C, RNA was extracted, and to the aqueous phase, 20% TCA was added, incubated on ice, centrifuged for 15 min at 10 000× g, and rinsed twice with ice cold 5% TCA. After dissolving the pellet, RNA was precipitated overnight, dissolved in RNase-free water, and aliquots were added to filters and counted in a scintillation counter. The labeled RNA was used for hybridization as follows. The linearized double stranded c-myc and actin plasmids were denatured and applied onto nitrocellulose using a slot blot apparatus. The filter was baked for 2 h at 80°C, prehybridized in hybridization solution (0.01 M TES, pH 7.4, 0.2% SDS, 0.01 M EDTA, 0.3 M NaCl, 1× Denhardt's, 100 mg/ml yeast tRNA, 100 mg/ml poly A) at 65°C for 2-6 h, and hybridized in the same hybridization solution but with added labeled RNA (1-5× 10 7 cpm/ml) for 30-40 h at 65°C. The filters were washed with 2×SSC at 65°C for 1 h followed by a 30 min wash at 37°C with 2×SSC and 10 mg/ml boiled RNase A. The filters were then exposed to a phosphorimager screen and the relative amounts of c-myc and b-actin nuclear run-on transcripts were quantitated by using the MD ImageQuant software (version 3.3, Molecular Dynamics, Sunnyvale, CA). Normalization was carried out by using b-actin as the internal control.
RNA purification and RNase protection assays
Cells were collected, washed in PBS (4°C), quickly frozen and stored at −70°C until all samples were ready for analysis. Total RNA was isolated using the TRIZOL Reagent according to the method provided by the manufacturer (GIBCO BRL, Gaitherburg, MD). This RNA was used for RNase protection assay. A plasmid pTRI-c-myc containing 251 bp c-myc cDNA was constructed.
32 P-labeled antisense c-myc RNA probe was synthesized by T7 promoter dependent RNA polymerase according to standard in vitro transcription protocols, and purified by gel electrophoresis. RNase protection assay was done with a kit from Ambion (Austin, TX). Basically RNA samples were mixed with the labeled probe. One-tenth volume of 5 M NH 4 OAc and 2.5 volumes of EtOH were added to the mixtures. The mixtures were then put in − 20°C for 15 min and pelleted by centrifugation. The pellets were resuspended in hybridization buffer, incubated at 42-45°C overnight, digested by RNase, and precipitated. The pellets were resuspended in gel loading buffer, denatured and subjected to electrophoresis. The gel was dried and exposed to a phosphorimager screen (Molecular Dynamics).
E6aluation of the acti6ity of human c-myc promoter
CEM-C7-14 cells were transfected with 15 mg of the human c-myc promoter-driven construct by electroporation [20] . The constructs, HBM-Luc and Mut-Luc, were kind gifts of Dr Linda Z. Penn (Department of Microbiology and Medical Biophysics at University of Toronto). HBM-Luc contains the sequence from − 2052 to +34 of human c-myc promoter [21] . The negative control construct consists of mutant Mut-Luc sequence from −107 to + 34 of the same promoter. After transfection, cells were selected with 400 mg/ml of G418. Recovered cells were incubated with EtOH or 1 mM of Dex for 24 h, then collected and lysed with 100 ml of lysis buffer provided in the luciferase assay kit from Promega (Madison, WI). After centrifugation at 13 000× g for 20 min at 4°C, 20 ml of supernatant was analyzed for luciferase activity using the kit from Promega and a Packard LumiCount Luminometer (Downers Grove, IL). Results were normalized with protein content.
Results
Dex suppresses the expression of c-myc mRNA in CEM-C7 cells
It has previously been shown that both c-myc mRNA and protein are suppressed in the clonal CEM-C7 cells after treatment with Dex. Since then, to ensure purity of phenotype, CEM-C7 cells were recloned and the subclone CEM-C7-14 was used in the studies of the human c-myc promoter reported this paper. Clone CEM-C7-14 has virtually the same diploid karyotype, growth, sensitivity to Dex, and GR content as found in the original CEM-C7 clone (unpublished data). Here it is confirmed that in the subclone, as in the mother clone CEM-C7 c-myc mRNA is reduced by Dex, using the RNase protection method. It is then further shown that c-Myc protein is suppressed in a dose-dependent fashion, as shown by immuno-blot (Fig. 1A,B) .
Dex suppresses c-myc at the transcriptional le6el
CEM-C7 cells were harvested and their nuclei isolated 0, 3, 6, 12, 24 h after treatment with 1 mM Dex. Using the full-length c-myc cDNA, nuclear run-on as- attenuation point in the c-myc gene. With it, one could determine whether Dex affected the initiation of c-myc transcription, and not down-stream effects on elongation or attenuation. At the time points indicated, nuclei were isolated and nuclear run-on experiments performed. Newly synthesized c-myc mRNA was suppressed to about the same extent as found with the full length cDNA probe of c-myc (Fig. 3) , suggesting that transcriptional initiation was primarily affected by Dex treatment.
Dex does not stablize c-myc mRNA
In order to determine the effect of Dex on the stability of c-myc mRNA, RNase protection assays were employed to determine the half-life of c-myc in says were performed. At all the time points tested, the newly synthesized c-myc mRNA levels were decreased in nuclei from the Dex-treated cells (Fig. 2) . A region near the exon 1/intron 1 junction has been reported as the region responsible for the elongation attenuation of c-myc mRNA transcription. Since the probe which was used was the full-length c-myc cDNA, it was possible that the decrease of c-myc mRNA transcripts was due to attenuation of c-myc mRNA transcription. In order to rule out this possibility, a plasmid containing the 5% flanking region and half of the first exon of the c-myc gene was employed. This plasmid will only bind to c-myc mRNA corresponding to the region prior to the cells grown with or without Dex. After incubation with 1 mM Dex or EtOH for 6 or 12 h, cells were treated with actinomycin D to block further RNA synthesis. Cells were collected at 0, 0.25, 0.5, 1, and 1.5 h after treatment with actinomycin D and RNA was prepared. The level of c-myc mRNA was determined by RNase protection assays. Fig. 4 shows that the half-life of c-myc mRNA is equal in the cells treated with Dex or EtOH vehicle. The half-life was 30 min at both time points which were tested.
Dex suppressed the acti6ity of a luciferase reporter gene dri6en by human c-myc promoter
Further proof that Dex regulates c-myc gene primarily at the transcriptional level comes from studies of the c-myc promoter-reporter gene. A plasmid carrying the sequence spanning −2052 -+ 34 (relative to P 2 ) of the human c-myc promoter driving a luciferase reporter gene (Fig. 5A ) was transfected into CEM-C7-14 cells along with a neomycin resistance conferring construct, PMTneo. After selection with 400 mg/ml of G418, the mass cell culture was treated with 1 mM Dex or EtOH vehicle for 24 h. Cells then were collected and lysed. Luciferase activities were determined for each sample and normalized with its protein concentration. In Fig.  5B , the data show clearly that Dex suppressed the c-myc promoter-driven luciferase activity by 50%. This further confirmed that the c-myc gene is primarily regulated by Dex at the transcriptional level, and provides initial evidence that a significant part of the regulatory region resides within the promoter fragment used. Dex showed minimal repression of luciferase activity from a shorter, mutant myc promoter construct, employed as a related non-specific promoter. It was concluded that the observed Dex repression requires sequences found in the non-mutated, longer c-myc promoter.
Discussion
In contrast to growth factor-dependent epithelioid and fibroblastic cells, in most lymphoid cell systems tested, apoptosis triggered by a variety of agents is preceded by a severe down-regulation of c-myc message and protein expression. Examples include glucocorticoid-evoked apoptosis of mouse S49 cells and human CEM and Jurkat cells [4, 14, 16] . Though the precise pathway by which c-myc suppression causes apoptosis has not been deciphered, the possibilities include loss of the Myc repression of death genes and/or down-regulation of vital genes that require Myc for activation.
Suppression of c-myc has been shown to be critical in the glucocorticoid-induced apoptotic pathway in human leukemic lymphoblasts of the CEM line. Both mRNA and protein of c-myc have been shown to be rapidly and deeply down-regulated by glucocorticoids in the receptor-positive, glucocorticoid-lysed CEM-C7 cells, but not in CEM-C1 cells, which have intact glucocorticoid receptors but resist glucocorticoid-induced apoptosis [22] or in ICR-27 cells, which lack functional receptors [23] . In CEM-C7 cells an antisense c-myc oligomer has been shown to block the expression of c-myc and induce cell death. Moreover, over-expression of c-myc driven by heterologous promoters all rescued Dex-induced cell death in CEM-C7 cells [2] . These observations strongly suggest that suppression of c-myc is crucial to glucocorticoid-induced apoptosis in this system. To be able to understand fully how c-myc is involved in this apoptotic pathway and especially what the upstream events of suppression of c-myc are, one has to know how c-myc gene is regulated.
Studies of various systems have shown that the expression of c-myc can be regulated at several levels, including transcription, post-transcription, and translation. In mouse lymphoid P1798 cells, Dex did not affect the stability of myc mRNA, but instead showed suppression at transcriptional initiation (shown by nuclear run-on assay) [15] . However, a study of CEM cells designated CEM 1.3 yielded data that Dex had no effect on transcription initiation. In that paper, assays were reported on nuclear run-on and mRNA half-life, each at a single time point after Dex administration [17] . More thorough analyses have been done in CEM-C7 and subclone CEM-C7-14 cells. Nuclear run-on assays were carried out at multiple time points up to 24 h after Dex treatment. Using a full length c-myc cDNA probe we show that transcription of cmyc is clearly suppressed by Dex to a minimum 30% of the control level at 6 h and remains at that level up to 24 h. To confirm that this suppression is at the level of transcription initiation, a plasmid containing some 5% region and half of exon 1 of c-myc was employed, as a probe designed so as to measure transcripts preceding the major known control point for elongation of c-myc transcripts. Newly synthesized cmyc mRNA is reduced by Dex treatment using this probe, to about the same extent as that observed using the full-length cDNA probe of c-myc. This clearly demonstrates that in the cells studied the c-myc gene is suppressed at the transcription initiation level. In addition, the half-life of c-myc in cells treated with or without Dex for 6 and 12 h was followed. At both time points, the half-life of c-myc is about 30 min, identical in EtOH (vehicle) or Dex treated CEM-C7 cells. Moreover, a luciferase plasmid under the control of the region from −2052 to + 34 of the c-myc promoter was transfected into CEM-C7 cells. The luciferase activity was suppressed by Dex to about 50% of the control. All these data are consistent and suggest that Dex regulates c-myc gene at the transcriptional, not the post-transcriptional, level in CEM-C7 cells. One cannot explain the discrepancy from the earlier report, save that CEM cells used in the prior report was designated CEM-1.3. No source and history of those CEM cells are given; therefore the relationship between CEM-1.3 and CEM-C7 cells is not clear. Hence, the discrepancy in results might be explained by the difference between cells, or by phenotypic drift and genotypic diversity, if CEM-1.3 cells share the origin of CEM-C7 cells. It does seem significant that in both rodent P1798 cells and human CEM-C7 cells, the negative regulation of c-myc by Dex was transcriptional. It was suspected that this is the general case.
